Inactive Instrument
Peregrine Pharmaceuticals Share Price Nasdaq
Stocks
US7136613046
Pharmaceuticals
| Market Cap | 799M 702M 653M 599M 1.13B 76.94B 1.14B 7.75B 3.03B 37.82B 3B 2.93B 131B | P/E 2023 |
2,007x | P/E 2024 | -3.42x |
|---|---|---|---|---|---|
| Enterprise Value | 964M 847M 788M 723M 1.36B 92.86B 1.38B 9.35B 3.65B 45.65B 3.62B 3.54B 158B | EV / Sales 2023 |
8.58x | EV / Sales 2024 | 4.64x |
| Free-Float |
98.58% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -2.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 14/09/2025 | |
Richard McAvoy
DFI | Director of Finance/CFO | - | 31/05/2026 |
David Stewart
CTO | Chief Tech/Sci/R&D Officer | - | 31/10/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.83% | +7.69% | - | - | 799M | |
| +0.63% | -3.06% | +16.50% | -10.25% | 66.74B | |
| -0.04% | +3.32% | +37.49% | +204.11% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| +1.90% | -5.07% | -56.99% | -56.52% | 38.25B | |
| +0.78% | -1.84% | +53.73% | -23.77% | 29.85B | |
| +0.84% | +0.36% | +67.62% | +87.37% | 23.51B | |
| -5.17% | -12.54% | +58.33% | -55.18% | 21.45B | |
| +1.31% | +3.24% | +81.47% | +159.24% | 16.47B | |
| +0.42% | -0.91% | +62.81% | +124.24% | 16.38B | |
| Average | +1.52% | -0.72% | +41.42% | +53.45% | 34.9B | |
| Weighted average by Cap. | +2.26% | +0.01% | +32.56% | +48.86% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 149M 131M 122M 112M 210M 14.37B 213M 1.45B 566M 7.07B 560M 548M 24.43B | 140M 123M 114M 105M 197M 13.47B 200M 1.36B 530M 6.62B 525M 514M 22.9B |
| Net income | 560K 492K 457K 420K 789K 53.93M 801K 5.43M 2.12M 26.51M 2.1M 2.06M 91.67M | -141M -124M -115M -105M -198M -13.55B -201M -1.37B -533M -6.66B -528M -517M -23.04B |
| Net Debt | 151M 133M 124M 113M 213M 14.56B 216M 1.47B 573M 7.16B 568M 555M 24.75B | 165M 145M 135M 124M 233M 15.92B 236M 1.6B 626M 7.83B 621M 607M 27.06B |
Employees
-
Sector
Pharmaceuticals
